Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Transdermal Drug Delivery Systems

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Future oncology (London, England)·2026

Same author

Exploration of experience and sustained engagement with a web-based cognitive rehabilitation intervention amongst patients with aggressive lymphoma: a qualitative sub-study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026

Same author

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease.

Internal medicine journal·2026

Same author

Early-Life Exposures and Risk of Multiple Myeloma: A Population-Based Case-Control Study in Australia.

International journal of cancer·2026

Same author

Diet and risk of multiple myeloma: findings from a case-control study.

The British journal of nutrition·2026

Search research articles

Related Experiment Video

Updated: May 22, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Romidepsin for cutaneous T-cell lymphoma.

H Miles Prince¹, Michael Dickinson

¹Department of Haematology, Peter MacCallum Cancer Centre, St Andrew's Place, East Melbourne, Victoria, Australia. Miles.Prince@petermac.org

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

|April 27, 2012

Summary

Romidepsin, a novel epigenetic therapy, offers prolonged responses for advanced cutaneous T-cell lymphomas (CTCL). This histone deacetylase inhibitor provides a tolerable option for patients with relapsed or refractory CTCL.

More Related Videos

An Engineered Split-TET2 Enzyme for Chemical-inducible DNA Hydroxymethylation and Epigenetic Remodeling

An Engineered Split-TET2 Enzyme for Chemical-inducible DNA Hydroxymethylation and Epigenetic Remodeling

Published on: December 18, 2017

Related Experiment Videos

Last Updated: May 22, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

An Engineered Split-TET2 Enzyme for Chemical-inducible DNA Hydroxymethylation and Epigenetic Remodeling

An Engineered Split-TET2 Enzyme for Chemical-inducible DNA Hydroxymethylation and Epigenetic Remodeling

Published on: December 18, 2017

Area of Science:

Oncology
Dermatology
Pharmacology

Background:

Cutaneous T-cell lymphomas (CTCL) are rare, with mycosis fungoides and Sezary syndrome being the most common types.
Advanced CTCL treatments like bexarotene and chemotherapy often lead to inevitable relapses.
Epigenetic modifiers, such as histone deacetylase inhibitors, represent a promising therapeutic avenue.

Purpose of the Study:

To evaluate the efficacy and safety of intravenous romidepsin for patients with relapsed or refractory CTCL.
To assess romidepsin's potential as a new treatment option for advanced CTCL.

Main Methods:

The study was based on two large Phase II clinical trials.
Intravenous romidepsin was administered to patients with relapsed and/or refractory CTCL.

Main Results:

Intravenous romidepsin demonstrated efficacy in a subset of patients with relapsed/refractory CTCL.
The treatment was associated with a tolerable side effect profile.
Romidepsin offers the potential for prolonged clinical responses.

Conclusions:

Romidepsin is an approved treatment for relapsed and/or refractory CTCL by the U.S. Food and Drug Administration.
This histone deacetylase inhibitor expands treatment options for advanced CTCL patients.
Romidepsin provides a valuable therapeutic choice with a manageable safety profile.